金城医药(300233.SZ)：子公司收到药品注册证书

Core Viewpoint - Jincheng Pharmaceutical (300233.SZ) announced that its wholly-owned subsidiaries, Beijing Jincheng Tail Pharmaceutical Co., Ltd. and Shanghai Jincheng Suzhi Pharmaceutical Co., Ltd., received drug registration certificates from the National Medical Products Administration for two products: Bisoprolol Amlodipine Tablets and Cefdinir Dry Suspension [1] Group 1 - Bisoprolol Amlodipine Tablets are a compound formulation consisting of Bisoprolol and Amlodipine, intended as an alternative therapy for hypertension, specifically for patients whose blood pressure is well-controlled with a single drug at the same dosage as the compound formulation [1] - Cefdinir Dry Suspension is an oral antibiotic used to treat mild to moderate infections in pediatric patients caused by specified sensitive strains of microorganisms [1]